PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.12%
Negative revenue growth while AVGO stands at 1.98%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-16.95%
Negative gross profit growth while AVGO is at 1.36%. Joel Greenblatt would examine cost competitiveness or demand decline.
-79.40%
Negative EBIT growth while AVGO is at 10.07%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-83.45%
Negative operating income growth while AVGO is at 10.07%. Joel Greenblatt would press for urgent turnaround measures.
-66.33%
Negative net income growth while AVGO stands at 9.66%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-66.18%
Negative EPS growth while AVGO is at 10.17%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-65.67%
Negative diluted EPS growth while AVGO is at 8.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.50%
Share reduction while AVGO is at 0.41%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.49%
Reduced diluted shares while AVGO is at 0.40%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
22.98%
Dividend growth above 1.5x AVGO's 4.98%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-9.73%
Negative OCF growth while AVGO is at 67.97%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-5.99%
Negative FCF growth while AVGO is at 125.40%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
103.30%
10Y revenue/share CAGR above 1.5x AVGO's 20.27%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
3.27%
5Y revenue/share CAGR under 50% of AVGO's 20.27%. Michael Burry would suspect a significant competitive gap or product weakness.
10.62%
3Y revenue/share CAGR under 50% of AVGO's 38.52%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
113.57%
10Y OCF/share CAGR above 1.5x AVGO's 64.06%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-6.01%
Negative 5Y OCF/share CAGR while AVGO is at 64.06%. Joel Greenblatt would question the firm’s operational model or cost structure.
20.95%
3Y OCF/share CAGR under 50% of AVGO's 348.39%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
165.64%
Below 50% of AVGO's 668.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-56.90%
Negative 5Y net income/share CAGR while AVGO is 668.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-55.02%
Negative 3Y CAGR while AVGO is 826.36%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
49.55%
Below 50% of AVGO's 169.79%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
35.46%
Below 50% of AVGO's 169.79%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
25.81%
Below 50% of AVGO's 123.14%. Michael Burry suspects a serious short-term disadvantage in building book value.
856.00%
Dividend/share CAGR of 856.00% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.92%
Dividend/share CAGR of 109.92% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
76.00%
3Y dividend/share CAGR of 76.00% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-24.21%
Firm’s AR is declining while AVGO shows 8.79%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.92%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-2.19%
Negative asset growth while AVGO invests at 5.41%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.41%
We have a declining book value while AVGO shows 5.25%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.07%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-8.21%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-5.08%
We cut SG&A while AVGO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.